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Background: Obesity is a disease that body energy intake is more than energy expenditure. In rodents and hu-
mans, there are two types of adipose tissue: White adipose tissue and Brown adipose tissue. Whereas WAT stores
excess energy as triacylglycerols, BAT is specialized in the production of heat.
Methods: PubMed and Cochrane databases were searched using the related keywords to find related documents
published until August 2019. In total, 115 published reports were reviewed in the study.
Results: Obesity associated with different diseases such as type 2 diabetes, cardiovascular disease, hypertension,
stroke, arthritis, and various types of cancer. Until recent years, it treated in various ways, such as diet, physical
activity, using medications, and surgical procedures. In recent years, Brown adipose tissue has been recognized
as a way to combat obesity and metabolic regulation.
Conclusions: Recent years are challenging times for all those working in the field of obesity and the pace of
discovery about obesity than ever before. During the last decades, many notable discoveries resulting from the
active research into the pathophysiological mechanisms controlling food intake, energy expenditure, and body
fat mass have been produced. Potential new avenues are opened for the future treatment of obesity by the recent
findings and its related disorders, although finding practical solutions to the problems posed by obesity could
ultimately depend as much on clever science and good clinical practice as on actively engaging the individual
and society alike to change everyday lifestyle.
1. Introduction
Obesity as the same as other metabolic disorders is a global problem
and it is a disease that body energy intake is more than energy ex-
penditure. Thus it can be treated by reducing food intake and/or in-
creasing energy expenditure (EE)(Kajimura and Saito, 2014). A large
portion of the resting energy expenditure is spent on thermoregulation
(Lee and Greenfield, 2015).
Adipose tissue is a central metabolic organ that controls energy
homeostasis and it can be subcategorized into WAT and BAT. WAT
stores excess energy as triglycerides (TG) and mobilizes it into free fatty
acid upon systemic demands. On other hand, BAT is a specialized
thermoregulatory organ that generates heat through uncoupling protein
1 (UCP1)-dependent non-shivering thermogenesis (cannon and
Nedergaard, 2004). Thus, activation of brown adipocyte metabolic
activity has been investigated as a potential therapeutic target to in-
crease energy expenditure, and ultimately, to counteract obesity and its
related metabolic diseases (Chondronikola et al., 2016).
This study, based on previous research in this area, will introduce
obesity, adipose tissue, its variants and the impact of BAT and obesity.
2. Methods
Two authors (Milad Dodangeh and Masoud Dodangeh) in-
dependently performed a search of PubMed and the Cochrane Database
of Systematic Reviews through August 2019. Search terms were
Obesity, Adipose tissue, White adipose tissue (WAT), Brown adipose
tissue (BAT) and the search was limited to publications in English. We
searched the keywords, both as free terms and in combination with
MeSH (medical subject headings) in PubMed.
Titles and abstracts of the resulting articles were examined, and full-
text articles were retrieved after excluding non-eligible ones.
Bibliographic references of recovered articles were examined to look for
additional studies.
3. Results
A total of 1158 observational studies were retrieved electronically
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from PubMed and Cochrane, and 97 studies were identified by other
sources. Endnote software was used to screen the references for dupli-
cation and 156 references were deleted. 283 articles were selected for
abstract assessment based on titles. After an abstract assessment, we




Although obesity has been recognized as significant global health,
social and economic problem for many years, the obesity epidemic is
continuing without signs of abatement (James, 2008). The obesity
epidemic is increasing sharply at an alarming rate; thus the pandemic of
obesity and overweight poses a severe threat to global public health and
nations (Kelly et al., 2008). Literature demonstrated that over 50% of
the world's population is in the overweight or obese category (Kelly
et al., 2008). In 1995, there were an estimated 200 million obese adults
worldwide. However, by the year 2000, the number had grown to 300
million and has continued to increase since then (Agha and Agha,
2017). In 2018, The prevalence of overweight and obesity in Iran was
34.5% and 21.5% (Kolahi et al., 2018).
Energy intake is more than energy expenditure in obese people.
Thus, Obesity and overweight caused by 1)High-calorie food 2)
Sedentary life (Cohen and Spiegelman, 2016; Scherer et al., 1995;
Stanford et al., 2013; Thomou et al., 2017). Accumulation of excess
dysfunctional adipose tissue is pathological. Obesity is a major biome-
dical challenge with its associated diseases, particularly for type 2
diabetes, cardiovascular disease, hypertension, stroke, arthritis, and
various types of cancer, imposing a substantial and increasing burden
on healthcare systems (Bray and Bellanger, 2006) and Governments
spend a great deal on the treatment of these diseases and these costs
increase sharply every year. The obesity and overweight treat simply, if
energy expenditure exceeds energy intake; thus reducing high-calorie
food and increasing exercise helps to combat obesity.
Although many years have been known that the metabolic impact of
sex hormones (estrogen, testosterone) effect on obesity, the hormonal
role of BAT related to male or female gender has only recently been
suggested.
4.2. Adipose tissue
Adipose tissue includes various cell types. The most important cell
types are adipocytes, adipose-derived stem cells (ADSC's), pre-
adipocytes, and immune cells. Increasing the size of existing mature
adipocytes (hypertrophy) and to some extent increasing in preadipocyte
and adipocyte numbers (adipogenesis) is the cause of adipose tissue
expands during periods of chronic positive energy imbalance (Prins and
O'rahilly, 1997; Rosen and Spiegelman, 2000).
There are two types of adipose tissue in rodents and humans (Frayn,
2010):
1) White adipose tissue (WAT)
2) Brown adipose tissue (BAT)
Whereas WAT stores excess energy as triacylglycerols, BAT is spe-
cialized in the production of heat (Frühbeck et al., 2009). WAT or BAT
has a unique developmental gene that is independent of the nutritional
state (Yamamoto et al., 2010).
4.2.1. White adipose tissue (WAT)
WAT stores energy in the form of triglycerides and releases energy
when the body needs energy such as during physical activity or fasting
(Frayn, 2010). WAT is characterized by various features, such as large
unilocular lipid droplets, limited mitochondria and is innervated by the
sympathetic and parasympathetic nervous systems (Bamshad et al.,
1998; Bartness and Bamshad, 1998; Bowers et al., 2004; Youngstrom
and Bartness, 1995). WAT exists in multiple locations in the body and
Fig. 1. Follow diagram of search results.
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two major subtypes are visceral and subcutaneous. Visceral WAT
(vWAT) accommodates around the internal organs and visceral WAT is
associated with insulin resistance, increased incidences of athero-
sclerosis, altered lipid profile, increased risk for type 2 diabetes, and
overall mortality (Carey et al., 1997; Nicklas et al., 2006; Ross et al.,
2008; Wang et al., 2005).
Subcutaneous WAT (scWAT) is like a peripherally located depot that
associate with increased insulin sensitivity and decreasing rates of type
2 diabetes, atherosclerosis, and dyslipidemia (Misra et al., 1997; Snijder
et al., 2003; Tankó et al., 2003).
4.2.2. Brown adipose tissue (BAT)
In 1551, Gessner identified Brown Adipose Tissue (BAT) in the inter-
scapular area of marmots (Smith and Horwitz, 1969). In rodents, BAT is
found primarily in the inter-scapular region and the axillae, whereas
minor amounts are found near to the thymus and in the dorsal midline
region of the thorax and abdomen. In the human neonates, BAT is found
in conspicuous depots mainly in the neck, mediastinum, surrounding
the great vessels and around the kidneys (Nedergaard et al., 2007). BAT
is more prominent in females and younger people and subjects. With
age, BAT declines disproportionately more in males. In newborn infants
about 5 percent of the body mass is BAT. BAT is very essential for in-
fants to avoid critical body cold (Kozak, 2010; Ravussin and Kozak,
2009).
The initial theory was that it was linked to hibernation, reflecting
the fact that marmots are hibernating animals. Sequentially this theory
was followed by the view that BAT was a part of the thymus
(1670–1817), an endocrine gland active in the formation of blood
(1817–1863), a modified form of fat tissue providing a reservoir for
food substances (1863–1902), and again as an endocrine gland
(1902–1961). In 1961, the effecter of non-shivering thermogenesis
(NST) and the “metabolic power” of brown adipocytes finally identified
(Smith and Horwitz, 1969).
There were three situations where BAT was understood to be highly
active (Smith and Horwitz, 1969):
1) During arousal from hibernation
2) In response to cold-exposure of certain adult mammals
3) In cold-stressed mammalian neonates
BAT is characterized by high levels of mitochondria (Cannon and
Nedergaard, 2004), multilocular lipid droplets (Rothwell and Stock,
1983), a high degree of vascularization (Fawcett, 1952), and sympa-
thetic innervation (Cannon and Nedergaard, 2004). UCP1 creates a
‘leaky’ proton channel (Matthias et al., 2000) in the mitochondria that
uncouples mitochondrial proton pumping from ATP production, re-
sulting in increased release of heat as part of the process of non-shi-
vering thermogenesis. Activated BAT increases sympathetic signaling
through norepinephrine, which stimulates β3-adrenergic receptors and
initiates lipolytic processes to liberate free fatty acids in the cytosol
(Bieber et al., 1975; Cannon and Nedergaard, 2004; Kuusela et al.,
1986).
4.3. Evidence for anti-obesity functions of BAT
Although many years have been known that the metabolic impact of
sex hormones (estrogen, testosterone) effect on obesity, the hormonal
role of BAT related to male or female gender has only recently been
suggested (Pfannenberg et al., 2010).
In rodents the early scientific evidence to ascribe BAT anti-obesity
functions came from experiments in which the surgical denervation or
excision of inter-scapular BAT was followed by an abnormal increase in
the amounts of WAT in those animals (Hansen and Kristiansen, 2006).
Targeted disruption of Cidea (cell-death inducing DFF45-like effector
A), which inhibits the uncoupling activity of the UCP1 protein, results
in lean mice that are resistant to diet-induced obesity (Zhou et al.,
2003). Additional examples of the relevance of BAT against the de-
velopment of obesity come from genetically obese mouse models like
the ob/ob and db/db strains where BAT is dysfunctional (Hansen and
Kristiansen, 2006). Finally, in most rodent models proneness to obesity
reportedly correlates with decreased BAT activity, whereas resistance to
obesity correlates with increased BAT function or the induction of
brown-adipocyte-like gene expression in WAT(Cannon and Nedergaard,
2004; Hansen and Kristiansen, 2006; Kozak and Anunciado-Koza,
2008). Adipocytes in culture, glucose uptake is directly adrenergically
stimulated, whereas stimulated thermogenesis is a prerequisite for FDG
uptake in BAT in vivo (Nedergaard et al., 2007).
The treatment of obesity is one of the thorniest issues in obesity.
Until recent years, BAT was an under-researched area in humans. Given
the current worldwide concern posed by the obesity epidemic, it is
exciting to contemplate translational applications related to a BAT-de-
rived increase in energy expenditure in obese individuals as a ther-
apeutic alternative based on a new conceptual strategy (Hanssen et al.,
2016, 2015).
The latest findings in humans provide evidence that defined regions
of BAT can be quantified noninvasively by FDG–PET/CT in adults
(Cypess et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen
et al., 2009). Until recent years it was assumed that only vestigial
amount of BAT was present in adulthood. Thus, stimulating BAT had
generally been discarded as a pharmacological option for human obe-
sity therapy. However, recently [18F]-2-fluoro-D-2-deoxy-D-glucose
(FDG) positron emission tomography (PET) has clearly shown that BAT
is present mainly in cervical, supraclavicular, axillary and paravertebral
regions of adult humans and might, thus, be considered to be both a
physiological and pharmaceutical target (Hany et al., 2002; Nedergaard
et al., 2007; Wijers et al., 2009).
The acute stimulatory effects of cold on BAT and prolonged cold
exposure produce not only BAT hyperplasia but also a remarkable in-
duction of beige adipocytes, both of them contribute to increased EE
(Saito, 2015; van Marken Lichtenbelt and Daanen, 2003). Van Ooijen
et al.(Vanooijen et al., 2004) showed that, during cold exposure, non-
shivering thermogenesis in winter is significantly higher compared with
summer, in the same volunteers. Moreover, subjects without BAT ac-
tivity show significantly lower non-shivering thermogenesis (Vijgen
et al., 2011; Yoneshiro et al., 2011). A study in healthy humans using
indirect calorimetry and stable isotopes showed that cold exposure in-
creased the resting metabolic rate of 14% in subjects who had detect-
able BAT levels and that this increase was fueled by both plasma-de-
rived glucose (30%) and free fatty acid oxidation (70%)(Chondronikola
et al., 2014). However, the relatively small contribution of fully active
BAT in average whole-body energy consumption does not make it a
viable weight loss goal.
In overweight and obese individuals BAT activity is reportedly
lower than in lean subjects (van Marken Lichtenbelt et al., 2009). Lit-
erature demonstrated that BMI and body fat percentage showed an
inverse correlation with BAT, resting metabolic rate exhibited a positive
correlation with BAT activity and higher levels of BAT might protect
against age-related obesity (Cypess et al., 2009). In overweight and
obesity treatment any intervention that causes a negative energy bal-
ance is guaranteed to be effective in producing weight loss. It has been
calculated that affecting energy balance by as little as 50–100 kcal/day,
an easily attainable target, could prevent weight gain in most of the
population (Hill et al., 2003). Even more, evidence-based guidelines
have recognized the clinical benefits of moderate 5–10% weight loss
(Hainer et al., 2008).
There are two strategies for generating functional adipose tissue:
1) The first one based on autologous BAT transplantation proved in-
effective. But free fat transplants rarely achieve sufficient functional
tissue because of deficient neovascularization and cell necrosis
(Tanzi and Farè, 2009).
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2) The second one is fat tissue bioengineering, the use of adult me-
senchymal cells and preadipocytes that appears to be more pro-
mising (Tseng et al., 2010).
BAT is a potential therapeutic target to improve the comorbidities
associated with obesity due to its inherent thermogenic capacity and its
ability to improve glucose metabolism (White et al., 2019).
5. Conclusions
Recent years are challenging times for all those working in the field
of obesity and the pace of discovery about obesity than ever before. The
next decade will be crucial for testing our collective ability to limit the
spread and impact of obesity. During the last decades, many notable
discoveries resulting from the active research into the pathophysiolo-
gical mechanisms controlling food intake, energy expenditure, and
body fat mass have been produced. In the next years, new candidate
signals are sure to be identified. In this context, it is difficult to envision
that in given clinical situations an ultimate all-powerful controller of
energy balance, able to over-ride all other regulatory systems, will be
found to be applied with therapeutic purposes. Noteworthy, from a
teleological perspective, the co-existence of numerous systems that are
designed to come into play under particular circumstances to control
specific aspects of feeding behavior and energy balance seems to prevail
over a single top-down hierarchy. It remains to be seen whether these
parallel mechanisms, which have evolved to protect energy stores that
are essential for survival and reproduction, can be counterbalanced and
superseded by a surplus of induced energy expenditure via BAT ma-
nipulation. Moreover, the benefit and full value of these new findings
will only be translated into practice if they can be integrated with the
everyday scenario of human obesity and if the acquired knowledge can
be usefully exploited in individuals. This is particularly challenging in
humans, where further layers of complexity are added by the numerous
psychological, social and cultural factors that shape eating behavior
and physical activity. Undoubtedly, the recent findings open potential
new avenues for the future treatment of obesity and its related dis-
orders, although finding practical solutions to the problems posed by
obesity could ultimately depend as much on clever science and good
clinical practice as on actively engaging the individual and society alike
to change everyday lifestyle.
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